OMGA Omega: Forward P/E Multiple
Omega Therapeutics is a leader in the field of epigenetic DNA reprogramming, bringing together the world's leading geneticists. The high authority of its management in mRNA therapy ensures the trust of major funds. The development of drugs for tissue regeneration is based on the OMEGA platform. The company's forward P/E for the coming year reflects market expectations, where the 0.00 metric determines the status of the current valuation parameter.
Financial and market metric breakdowns for Omega Therapeutics Corp (OMGA)
- stock quotes and analyst forecast:
- company stock capitalization data:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital Omega Therapeutics|OMGA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Omega Therapeutics|OMGA - Company Cumulative Debt|Debt to Book Capitalization Ratio Omega Therapeutics Inc|OMGA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Omega Therapeutics|Quick Liquidity omegatherapeutics.com
- financial results and valuation multiples details:
OMGA - Profit After Tax|Projected Future Earnings Omega Therapeutics|OMGA - Market Cap to Earnings|Projected Price to Earnings Omega|OMGA - PEG Multiple|Enterprise Value to EBITDA Ratio Omega Therapeutics Inc|OMGA - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Omega Therapeutics|OMGA - Net earnings per share for the last four quarters|Quarterly EPS earnings growth omegatherapeutics.com|OMGA - Net earnings per share growth this year|Net earnings per share growth forecast for next year Omega Therapeutics
- sales volume and revenue information:
Analysis of all company metrics:OMGA Omega Therapeutics, Inc.
For Omega Therapeutics (OMGA), which is developing epigenetic programming via the OMEGA platform, the company's forward P/E ratio serves as an indicator of market expectations regarding the future monetization of its oncology developments. This multiple is calculated as the ratio of the current share price to the expected net income for the following year, allowing investors to assess the premium paid for the future success of the biotechnology business.
Direct competitors
Forward P/E Multiple TEM|Qiagen NV (QGEN) - Forward Price to Earnings Multiple|Forward P/E Multiple IONS (Ionis Pharma)|Forward P/E Multiple Repligen Inc. RGEN|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (crisprtx.com)|WGS (GeneDx) - Projected Price to Earnings|RARE: Market Cap to Future Earnings Ratio|BEAM (Beam Therapeutics Corp) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Forward P/E Multiple TWST|TXG - Projected Price to Earnings Ratio|Future Price to Earnings Intellia Therapeutics, Inc. NTLA|Future Price to Earnings Multiple STOK|BioLife Corp - Forward P/E Multiple|WVE - Forward P/E Multiple|Maze Therapeutics Inc (MAZE) - Future Price to Earnings|Price to Expected Earnings Ratio SION (sionnatx.com)|PRME (Prime Medicine) - Forward P/E Multiple|Projected Price to Earnings Ratio Taysha Gene Therapies Inc TSHA|Projected Price to Earnings QURE (uniQure Corp)|Forward P/E Multiple MeiraGTx Corp (MGTX)|REGENXBIO Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio SLDB (solidbio.com)|Ocugen - Forward P/E Multiple|Market Cap to Projected Earnings Pacific Biosciences of California, Inc. PACB|BNTC: Forward P/E Multiple|Projected Price to Earnings Design Corp|Future Price to Earnings Rocket Pharmaceuticals|4dmoleculartherapeutics.com (FDMT) - Market Cap to Projected Earnings|Future Price to Earnings Lexeo Therapeutics (LXEO)|KRRO - Projected Price to Earnings Ratio|Future Price to Earnings Editas EDIT|SLN - Projected Price to Earnings|ProQR Therapeutics NV - Forward P/E Multiple|Forward Price to Earnings Multiple Codexis, Inc. (CDXS)|SGMO: Forward P/E Multiple|Nautilus Bio (NAUT) - Forward P/E Multiple|MGX (Metagenomi, Inc) - Forward P/E Multiple|Price to Future Earnings Ratio DTIL (Precision BioSciences Inc.)|Future Price to Earnings Generation Bio Co. (GBIO)|boundlessbio.com - Price to Future Earnings Ratio|Forward P/E Multiple XCUR (Exicure)|Forward P/E Multiple Imunon Inc IMNN|PHIO - Future Price to Earnings|Projected Price to Earnings Ratio Mustang Bio, Inc.|transcodetherapeutics.com (RNAZ) - Future Price to Earnings|Projected Price to Earnings Bionano Genomics|APDN (Applied DNA Sciences, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio bluebird bio Inc. BLUE|Forward P/E Multiple IPA|Singular Genomics Corp (OMIC) - Forward Price to Earnings Multiple|Forward P/E Multiple RGLS (Regulus Therapeutics)|Forward P/E Multiple syros.com SYRS|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Projected Price to Earnings
